Orlova A

Family name	Orlova
Given name	Anna
Initials	A
ORCID	ORCID 0000-0001-6120-2683
Affiliations	Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden. Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

45 publications

PubMed DOI Crossref

A preclinical study on the influence of linkers in [68Ga]Ga-NOTA-X-RM26 radiotracers for PET imaging of GRPR expression.

Olaniran Håkansson E, Zelepukin IV, Obeid K, ..., Odell LR, Kanellopoulos P

EJNMMI Res 15 (1) 104 [2025-08-07; online 2025-08-07]

PubMed DOI Crossref

Evaluation of ABD-Linked RM26 Conjugates for GRPR-Targeted Drug Delivery.

Nagy Á, Abouzayed A, Kanellopoulos P, ..., Orlova A, Eriksson Karlström A

ACS Omega 9 (34) 36122-36133 [2024-08-27; online 2024-08-15]

PubMed DOI Crossref

Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer.

Kanellopoulos P, Bezverkhniaia E, Abouzayed A, ..., Tolmachev V, Orlova A

ACS Omega 9 (16) 18608-18616 [2024-04-23; online 2024-04-10]

PubMed DOI Crossref

GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics.

Obeid K, Kanellopoulos P, Abouzayed A, ..., Maina T, Orlova A

Pharmaceutics 16 (4) - [2024-04-08; online 2024-04-08]

PubMed DOI Crossref

Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m.

Bezverkhniaia E, Kanellopoulos P, Rosenström U, Tolmachev V, Orlova A

Int J Mol Sci 25 (7) - [2024-03-23; online 2024-03-23]

PubMed DOI Crossref

Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA).

Bezverkhniaia E, Kanellopoulos P, Abouzayed A, ..., Tolmachev V, Orlova A

Int J Mol Sci 24 (24) - [2023-12-12; online 2023-12-12]

PubMed DOI Crossref

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics.

Abouzayed A, Kanellopoulos P, Gorislav A, ..., Nock BA, Orlova A

Biomolecules 13 (7) - [2023-07-14; online 2023-07-14]

PubMed DOI Crossref

The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity.

Abouzayed A, Borin J, Lundmark F, ..., Chernov V, Orlova A

Diagnostics (Basel) 13 (9) - [2023-05-02; online 2023-05-02]

PubMed DOI Crossref

Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors.

Chernov V, Rybina A, Zelchan R, ..., Tolmachev V, Orlova A

Cancers (Basel) 15 (6) - [2023-03-07; online 2023-03-07]

PubMed DOI Crossref

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.

Xu T, Schulga A, Konovalova E, ..., Tolmachev V, Vorobyeva A

Int J Mol Sci 24 (3) - [2023-02-02; online 2023-02-02]

PubMed DOI Crossref

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation.

Lundmark F, Abouzayed A, Rinne SS, ..., Rosenström U, Orlova A

Cancers (Basel) 15 (2) - [2023-01-10; online 2023-01-10]

PubMed DOI Crossref

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis.

Liu Y, Güler R, Liao Y, ..., Tolmachev V, Frejd FY

Pharmaceutics 14 (11) - [2022-11-19; online 2022-11-19]

PubMed DOI Crossref

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.

Li M, Zelchan R, Orlova A

Biomedicines 10 (10) - [2022-10-10; online 2022-10-10]

PubMed DOI Crossref

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.

Rinne SS, Yin W, Borras AM, ..., Orlova A, Gräslund T

Biomedicines 10 (6) - [2022-05-31; online 2022-05-31]

PubMed DOI Crossref

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands.

Lundmark F, Olanders G, Rinne SS, ..., Orlova A, Rosenström U

Pharmaceutics 14 (5) - [2022-05-20; online 2022-05-20]

PubMed DOI Crossref

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.

Yin W, Xu T, Altai M, ..., Gräslund T, Orlova A

Pharmaceutics 13 (11) - [2021-11-21; online 2021-11-21]

PubMed DOI Crossref

HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers.

Rinne SS, Leitao CD, Abouzayed A, ..., Löfblom J, Orlova A

Cancers (Basel) 13 (19) - [2021-09-24; online 2021-09-24]

PubMed DOI Crossref

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.

Xu T, Vorobyeva A, Schulga A, ..., Tolmachev V, Deyev SM

Cancers (Basel) 13 (16) - [2021-08-04; online 2021-08-04]

PubMed DOI Crossref

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.

Deyev SM, Xu T, Liu Y, ..., Tolmachev V, Vorobyeva A

Cancers (Basel) 13 (14) - [2021-07-17; online 2021-07-17]

PubMed DOI Crossref

PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.

Rinne SS, Orlova A, Tolmachev V

Int J Mol Sci 22 (7) - [2021-04-01; online 2021-04-01]

PubMed DOI Crossref

66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26.

Rinne SS, Abouzayed A, Gagnon K, Tolmachev V, Orlova A

Sci Rep 11 (1) 3631 [2021-02-11; online 2021-02-11]

PubMed DOI Crossref

Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer.

Abouzayed A, Rinne SS, Sabahnoo H, ..., Tolmachev V, Orlova A

Pharmaceutics 13 (2) - [2021-01-30; online 2021-01-30]

PubMed DOI Crossref

Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.

Baun C, Mitran B, Rinne SS, ..., Orlova A, Thisgaard H

Molecules 25 (24) - [2020-12-18; online 2020-12-18]

PubMed DOI Crossref

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer.

Abouzayed A, Tano H, Nagy Á, ..., Eriksson Karlström A, Orlova A

Pharmaceutics 12 (10) - [2020-10-16; online 2020-10-16]

PubMed DOI Crossref

Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.

Vorobyeva A, Bezverkhniaia E, Konovalova E, ..., Deyev S, Tolmachev V

Molecules 25 (20) - [2020-10-14; online 2020-10-14]

PubMed DOI Crossref

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model.

Lundmark F, Abouzayed A, Mitran B, ..., Rosenström U, Orlova A

Pharmaceutics 12 (7) - [2020-07-01; online 2020-07-01]

PubMed DOI Crossref

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.

Leitao CD, Rinne SS, Altai M, ..., Ståhl S, Orlova A

Pharmaceutics 12 (6) - [2020-06-13; online 2020-06-13]

PubMed DOI Crossref

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.

Vorobyeva A, Konovalova E, Xu T, ..., Tolmachev V, Deyev S

Int J Mol Sci 21 (9) - [2020-05-07; online 2020-05-07]

PubMed DOI Crossref

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.

Rinne SS, Dahlsson Leitao C, Saleh-Nihad Z, ..., Löfblom J, Orlova A

Int J Mol Sci 21 (6) - [2020-03-13; online 2020-03-13]

PubMed DOI Crossref

Affibody Molecules as Targeting Vectors for PET Imaging.

Tolmachev V, Orlova A

Cancers (Basel) 12 (3) - [2020-03-11; online 2020-03-11]

PubMed DOI Crossref

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.

Rinne SS, Xu T, Dahlsson Leitao C, ..., Tolmachev V, Vorobyeva A

Int J Mol Sci 21 (4) - [2020-02-15; online 2020-02-15]

PubMed DOI Crossref

Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.

Mitran B, Rinne SS, Konijnenberg MW, ..., Rosenström U, Orlova A

Int. J. Cancer 145 (12) 3347-3358 [2019-12-15; online 2019-05-23]

PubMed DOI Crossref

Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.

Rinne SS, Dahlsson Leitao C, Gentry J, ..., Löfblom J, Orlova A

Sci Rep 9 (1) 17710 [2019-11-27; online 2019-11-27]

PubMed DOI Crossref

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.

Mitran B, Thisgaard H, Rinne S, ..., Orlova A, Rosenström U

Sci Rep 9 (1) 17086 [2019-11-19; online 2019-11-19]

PubMed DOI Crossref

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Mitran B, Varasteh Z, Abouzayed A, ..., Orlova A, Rosenström U

Cancers (Basel) 11 (9) - [2019-09-14; online 2019-09-14]

PubMed DOI Crossref

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.

Ding H, Altai M, Rinne SS, ..., Gräslund T, Orlova A

Cancers (Basel) 11 (8) - [2019-08-14; online 2019-08-14]

PubMed DOI Crossref

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart.

Oroujeni M, Abouzayed A, Lundmark F, ..., Tolmachev V, Rosenström U

Pharmaceutics 11 (8) - [2019-08-02; online 2019-08-02]

PubMed DOI Crossref

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.

Abouzayed A, Yim CB, Mitran B, ..., Rosenström U, Orlova A

Pharmaceutics 11 (7) - [2019-07-23; online 2019-07-23]

PubMed DOI Crossref

Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3.

Vorobyeva A, Schulga A, Konovalova E, ..., Tolmachev V, Deyev SM

Sci Rep 9 (1) 9405 [2019-06-28; online 2019-06-28]

PubMed DOI Crossref

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging.

Vorobyeva A, Schulga A, Rinne SS, ..., Deyev S, Tolmachev V

Int J Mol Sci 20 (12) - [2019-06-21; online 2019-06-21]

PubMed DOI Crossref

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.

Rosestedt M, Andersson KG, Rinne SS, ..., Tolmachev V, Orlova A

Sci Rep 9 (1) 6779 [2019-05-01; online 2019-05-01]

PubMed DOI Crossref

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.

Dahlsson Leitao C, Rinne SS, Mitran B, ..., Löfblom J, Orlova A

Int J Mol Sci 20 (5) - [2019-03-02; online 2019-03-02]

PubMed DOI Crossref

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.

Rinne SS, Leitao CD, Mitran B, ..., Löfblom J, Orlova A

Sci Rep 9 (1) 655 [2019-01-24; online 2019-01-24]

PubMed DOI Crossref

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.

Altai M, Leitao CD, Rinne SS, ..., Löfblom J, Orlova A

Cells 7 (10) - [2018-10-11; online 2018-10-11]

PubMed DOI Crossref

Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors.

Oroujeni M, Garousi J, Andersson KG, ..., Orlova A, Tolmachev V

Cells 7 (9) - [2018-09-18; online 2018-09-18]